Title : Recombinant human heterodimeric
IL-15 complex displays extensive and reproducible N- and O-linked glycosylation
Abstract :
- Human interleukin 15 ( IL-15 ) circulates in blood as a stable molecular complex with the soluble IL-15 receptor alpha ( sIL-15Rα)
- This heterodimeric IL-15 : sIL-15Rα complex (het IL-15 ) shows therapeutic potential by promoting the growth, mobilization and activation of lymphocytes and is currently evaluated in clinical trials
- Favorable pharmacokinetic properties are associated with the heterodimeric formation and the glycosylation of het IL-15 , which, however, remains largely uncharacterized
- We report the site-specific N- and O-glycosylation of two clinically relevant large-scale preparations of HEK293-derived recombinant human het IL-15
- Intact IL-15 and sIL-15Rα and derived glycans and glycopeptides were separately profiled using multiple LC-MS/MS strategies
- IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures
- The two potential IL-15 N-glycosylation sites ( Asn71 and Asn112 ) located at the IL-2 receptor interface were unoccupied
- Mass analysis of intact IL-15 confirmed its N-glycosylation and suggested that Asn79-glycosylation partially prevents Asn77-deamidation
- IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- The sialoglycans displayed α2-3- and α2-6-NeuAc-type sialylation
- Non-human, potentially immunogenic glycoepitopes (e.g. N-glycolylneuraminic acid and α-galactosylation) were not displayed by het IL-15
- Highly reproducible glycosylation of IL-15 and sIL-15Rα of two batches of het IL-15 demonstrated consistent manufacturing and purification
- In conclusion, we document the heterogeneous and reproducible N- and O-glycosylation of large-scale preparations of the therapeutic candidate het IL-15
- Site-specific mapping of these molecular features is important to evaluate the consistent large-scale production and clinical efficacy of het IL-15
Output (sent_index, trigger,
protein,
sugar,
site):
- 12. glycosylation, , IL-15, -, -
- 3. glycosylation, , IL-15, -, -
- 5. glycopeptides, , -, -, glycopeptides
- 6. carried, , -, biosynthetically-related N-glycans, Asn107
- 6. carried, , -, biosynthetically-related N-glycans, Asn79
- 6. α1-6-core-fucosylated, , -, mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures, -
- 7. N-glycosylation, , -, -, Asn71 and Asn112
- 7. N-glycosylation, , -, -, sites
- 7. sites, , -, -, Asn71 and Asn112
- 7. sites, , -, -, sites
- 9. O-glycosylated, , sIL, -, -
- 9. contained, , IL-15, no O-glycans, -
- 9. hexasaccharides, , -, Ser158, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. hexasaccharides, , -, Ser160, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. hexasaccharides, , -, Thr156, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. hexasaccharides, , -, Thr2, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. hexasaccharides, , -, Thr81, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. hexasaccharides, , -, Thr86, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. sialylated, , -, core 1, -
Output(Part-Of) (sent_index,
protein,
site):
- 6. IL-15, Asn79
- 6. sIL, Asn107
- 7. IL-15, Asn71 and Asn112
- 7. IL-15, sites
*Output_Site_Fusion* (sent_index,
protein,
sugar,
site):
- 6. IL-15, biosynthetically-related N-glycans, Asn79
- 6. sIL, biosynthetically-related N-glycans, Asn107
- 7. IL-15, -, Asn71 and Asn112
- 9. sIL, Ser158, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. sIL, Ser160, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. sIL, Thr156, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. sIL, Thr2, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. sIL, Thr81, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160
- 9. sIL, Thr86, Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160